September 4, 2011
Lady Ga Ga / Stefani Germanotta
% Sara Newkirk, Agent
WmE2 Endeavor-L A
9601 Wilshire Blvd., 3rd Floor
Beverly Hills, CA 90210
Tel: 310-248-2000 FAX 310-248-2020
Hello, Lady Ga Ga,
We are aware of the important work that you have championed to promote women’s prevention awareness of the risks of HIV/AIDS. You may count us among your ardent supporters (and fans). We would very much like to discusswith you our condom research/development projects and perhaps explore possibilities thatmayalignthe ORIGAMI Condoms™ launch in 2014, with your HIV prevention objectives.
As a gay man successfully living with HIV since 1994, I learned ofthe far-reaching effects of the virusaftermy infection through a broken condom.Indeed, as you may be aware, a near-universal dissatisfaction with traditional latex condoms marks the history of condom usage, a result of poor design anda lack of user-friendliness. We have developed a new concept that changes the basic approach to condom design. We havepatented three unique condoms, whichmay be a game changer that breaks the usage barriers surrounding prevention efforts around the world.
The inventionshave turned a dark period in my life into a positive force that inspiredour new approach to condom design; a prevention method that people actually enjoy using anda reverse of the long held belief that condoms are not pleasurable. Ourdesign theory has been embraced with the substantial support of National Institutes of Health (NIH) research grants, to develop these unique devices.
We have received$2.5M of research funding from the Eunice Kennedy ShriverNational Institute of Child Health and Human Development (NICHD)The National Institute of Allergy and Infectious Diseases (NIAID). Phase 1 research allowed us to develop thisnew generation of prevention strategies to help resolve issues that prevent the old latex condom (designed in 1921) from being used as effectively and extensively as needed in today's health environment.
Our product development and clinical trials are conducted in collaboration with several prestigious research groups; the Women’s Global Health Imperative at RTI International (San Francisco), the California Family Health Council (L A), and the Fenway Institute (Boston).
2
There are three important developments that we would like to share with you: first, the ORIGAMI Female Condom™is easily pre-inserted before intercourse and is intended to provide women with a safer, user-friendly device that enhances the sexual experience for both partners, and gives women a non-negotiable voice in the decision to use a condom.;Ssecond, the ORIGAMI R.A.I. Condom™, uniquely designed for receptive anal intercourse, is a pioneering concept; . iIt is the first condomto bereviewed by the FDA for anal intercourse,the primary means of HIV transmission among gay men. Commercial male and female condoms are FDA approvedonly for vaginal intercourse; and third, the ORIGAMI Male Condom™, a non-rolled, condom thatcould improves sensation for both partners (M/F). These new condoms provide superior strength made of our unique, viral-impermeable, biocompatiblesilicone. Each is a technological advancement in the field of reproductive health and HIV/AIDS prevention.
Wewould welcome an opportunity to learnhow we could support mutual objectives and your HIV prevention mission. Please let us know if this would be of interest to merit a discussion. If so, we would like to meet with you toreviewour project developments.We have an upcoming design review with our medical consultants for the ORIGAMI Female Condom™at our Culver City, CA office in late September. You are welcome to join us then or otherwise at your convenience when your schedule permits.
I wish you a peaceful day andI look forward to hearing from you.
Sincerely,
Danny Resnic
Inventor
Principle Investigator of Clinical Research
STRATA VARIOUS PRODUCT DESIGN
4445 Overland Avenue
Culver City, CA 90230
Tel: 310-280-9861 Fax: 440-508-2984